TransPerfect, a provider of e-clinical technologies to the life sciences industry, announced that INC Research, a therapeutically focused clinical research organization (CRO), has selected Trial Interactive as its global electronic Trial Master File (eTMF) solution. Trial Interactive is a secure, web-based platform that reduces the redundancies inherent in paper-based TMF management.
"We chose Trial Interactive as our eTMF solution because it offers the greatest compatibility with current and potential customers,” said Todd Esporas, Executive Director of Clinical Development Services at INC Research. As one of the top 10 global CROs, optimizing the collection and management of TMFs worldwide is a critical task for INC Research. Trial Interactive enables INC Research to deliver trials more efficiently by allowing real-time access to global project documentation, eliminating much of the travel and shipping associated with TMF reviews and reconciliation, and providing a real-time metrics dashboard to enhance communications with customers and stakeholders. Trial Interactive’s interface is available in more than 20 languages, which will enable INC Research to deploy the solution in the local language of the end user, making it ideal for global study teams, sponsors, and investigative site personnel involved in the conduct of multinational clinical trials.
Michael Smyth, General Manager of TransPerfect’s Life Science Solutions division, stated, “We’re very proud that INC Research has chosen Trial Interactive as its eTMF solution. INC’s global reach and commitment to utilizing technology should only serve to benefit their study sponsors as they seek to become more efficient in conducting global clinical trials.”
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.